{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:20:25Z","timestamp":1789014025635,"version":"build-2803163510"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,10,20]],"date-time":"2003-10-20T00:00:00Z","timestamp":1066608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2003,11]]},"abstract":"<jats:p><jats:bold>Summary.<\/jats:bold> We have reviewed the outcome after relapse in a cohort of 505 children with acute lymphoblastic leukaemia (ALL) seen at a single institution. The majority of relapses (74%) occurred within 3\u2003years from diagnosis, and most involved the bone marrow alone or with overt extramedullary relapse. Early relapse was more common in children with T\u2010ALL and those with unfavourable cytogenetics. Factors influencing second remission included length of first remission and type of relapse. Children who had not received previous cranial irradiation had a superior survival. The German relapse score involving length of first remission, site of relapse and immunophenotype was highly predictive of outcome: event\u2010free survival with 95% confidence intervals at 6\u2003years for patients who received modern treatment [intensive chemotherapy or bone marrow transplantation (BMT)] was 78% (51\u201392%) for standard risk, 41% (33\u201349%) for intermediate risk and 19% (10\u201331%) for highest risk. Retrospective comparison of BMT with chemotherapy showed no difference in the intermediate\u2010risk group but a possible advantage in the highest risk group. Follow\u2010up of 235 patients who relapsed after chemotherapy and received a third course of treatment showed an extremely high early attrition rate, but a small number of patients survived in third remission. We conclude that new approaches are needed to individualize therapy in intermediate\u2010risk patients and to improve the outcome for those in the highest risk group. Only a small number of children can be treated effectively in third remission.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2003.04584.x","type":"journal-article","created":{"date-parts":[[2003,10,20]],"date-time":"2003-10-20T07:53:32Z","timestamp":1066636412000},"page":"396-405","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Long\u2010term follow\u2010up of relapsed childhood acute lymphoblastic leukaemia"],"prefix":"10.1111","volume":"123","author":[{"given":"Judith M.","family":"Chessells","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Veys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Kempski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Henley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Leiper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Hann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,10,20]]},"reference":[{"key":"e_1_2_20_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2231"},{"key":"e_1_2_20_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701013"},{"key":"e_1_2_20_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00776.x"},{"key":"e_1_2_20_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.62.2.172"},{"key":"e_1_2_20_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb03251.x"},{"key":"e_1_2_20_7_1","first-page":"1275","article-title":"Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL Trials. Report from the Medical Research Council Working Party on childhood leukaemia","volume":"8","author":"Chessells J.M.","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_20_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90164-7"},{"key":"e_1_2_20_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980401)82:7<1387::AID-CNCR24>3.0.CO;2-1"},{"key":"e_1_2_20_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401704"},{"key":"e_1_2_20_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02668.x"},{"key":"e_1_2_20_12_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008381801403"},{"key":"e_1_2_20_13_1","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood.V78.5.1166.1166","article-title":"Six\u2010year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL\u2010REZ BFM 85). A relapse study of the BFM group","volume":"78","author":"Henze G.","year":"1991","journal-title":"Blood"},{"key":"e_1_2_20_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)03098-5"},{"key":"e_1_2_20_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.11.4072"},{"key":"e_1_2_20_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01891.x"},{"key":"e_1_2_20_17_1","first-page":"408","article-title":"Improvement in treatment for children with acute lymphoblastic leukaemia","author":"Medical Research Council","year":"1986","journal-title":"Lancet"},{"key":"e_1_2_20_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1984.201"},{"key":"e_1_2_20_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1834.x"},{"key":"e_1_2_20_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.1"},{"key":"e_1_2_20_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.62.1.12"},{"key":"e_1_2_20_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3406"},{"key":"e_1_2_20_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401254"},{"key":"e_1_2_20_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.7.2412.h8002412_2412_2418"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2003.04584.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2003.04584.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2003.04584.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T22:34:51Z","timestamp":1697409291000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2003.04584.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,20]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["10.1046\/j.1365-2141.2003.04584.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04584.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,20]]},"assertion":[{"value":"2003-10-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}